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Abstract
In cancer surgery, intra-operative assessment of the tumor-free margin, which is critical for the
prognosis of the patient, relies on the visual appearance and palpation of the tumor. Optical
imaging techniques provide real-time visualization of the tumor, warranting intra-operative
image-guided surgery. Within this field, imaging in the near-infrared light spectrum offers two
essential advantages: increased tissue penetration of light and an increased signal-to-
background-ratio of contrast agents. In this article, we review the various techniques, contrast
agents, and camera systems that are currently used for image-guided surgery. Furthermore, we
provide an overview of the wide range of molecular contrast agents targeting specific hallmarks
of cancer and we describe perspectives on its future use in cancer surgery.
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Introduction
O
ver the last decades, imaging technologies have made
significant developments, resulting in their current
perpetual role in clinical oncology. The field has expanded
greatly and now comprises various modalities, including
ultrasonography, computed tomography (CT), magnetic
resonance imaging (MRI), positron emission tomography
(PET), and single-photon-emission computed tomography.
Because each modality has its specific advantages and
disadvantages, the combination of different techniques has
become standard practice for tumor detection, staging, and
treatment evaluation [1].
However, when surgery is required, translation of these
images to the operation field remains a major challenge for
the surgeon. Visual appearance and palpation is the only
way to discriminate between tumor and normal tissue and
consequently determine an adequate tumor-free margin
during surgery. This is a critical aspect of oncologic surgery
because, apart from tumor characteristics (i.e., stage, differ-
entiation grade), complete surgical removal is pivotal for the
prognosis of the patient.
Real-time imaging technologies could offer the possibility
to put the images right under the hands of the surgeon,
warranting intra-operative image-guided surgery. In order to
detect malignant cells or tissues, the various hallmarks of
cancer can be used as a target for imaging strategies: increased
growth and growth factor signaling receptors, limitless
replicative potential, sustained angiogenesis, and increased
proteolytic activity resulting in tissue invasion and metastasis
(Fig. 1)[ 2].
The characteristic of increased metabolism is exploited in
PET technology, using the glucose-mimetic 2-deoxy-2-[
18F]
fluoro-D-glucose. Tumor cells most frequently use glycol- Correspondence to: Stijn Keereweer; e-mail: s.keereweer@erasmusmc.nlysis for energy generation, resulting in an increased glucose
metabolism and the overexpression of glucose transporters
(GLUTs) [3]. 2-Deoxy-2-[
18F]fluoro-D-glucose is taken up
by metabolically active cells, making it applicable in a wide
range of tumors [4]. For intra-operative evaluation of tumor
localization and margin status in breast cancer surgery, a
hand-held PET probe to detect the high-energy gamma rays
during surgery has been developed [5].
Although very useful for diagnostic applications, the PET
imaging technology has several disadvantages for widely used
intra-operative practice. Due to its limited spatial resolution,
small tumors (G1 cm) have proven difficult to detect by this
hand-heldprobe[5].Furthermore,theuseofPETtechnologyis
restricted to specialized centers for logistical, practical, and
financial reasons. Radiochemists, a cyclotron, and specialized
waste processing facilities are required in order to produce the
radiopharmaceuticals. Although radiation exposure for the
patient and operation personnel is minimized due to tracer
amounts of the very short-lived agents, the short half-life time
limits the time frame in which the agents have to be
administered. This requires careful planning with the risk of
high expenses when an operation procedure is delayed.
Interesting developments have been made in the last years
usingRamanspectroscopy. A Ramanspectrumisgeneratedby
a shift in frequency in the incident excitation light of tissue,
resulting in in-elastic scattering. The shift in frequency is
caused by discrete changes in emergent light, above and below
the wavelength of the incident photons, due to the vibrational
frequencies of the bio-molecules that constitute the tissue.
There are several characteristic features of spectroscopy which
make it attractive for oncological applications. Specific lesions
can be identified using optical fibers for in vivo measurements.
Furthermore, they do not require the use of dyes, labels, or
other contrast-enhancing agents, implicating that tissues can be
studied in their native states.
Various groups have performed Raman spectroscopic
studies where spectral differences have been reported
between normal and cancerous lesions. In this way, the
detection of cancers and precancers has been described in
skin, mucosal surfaces, and solid organs [6–8].
These interesting results suggest its relevance to clinical
oncological applications. However, several hurdles have yet
to be overcome. The Raman effect comprises a very small
fraction (∼1i n1 0
7) of the incident photons, resulting in
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Fig. 1. Hallmarks of cancer and their targets for optical imaging. EGF epidermal growth factor, cRGD cyclic arginine-glycine-
aspartate, VEGF vascular endothelial growth factor, NIRF near-infrared fluorescence. Edited from with kind permission from
Kroemer, G & Pouyssegur, J; Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008 Jun;13(6):472-82.
200 S. Keereweer, et al.: Optical Image-guided Surgerymuch weaker signals than autofluorescence. Hence, these
signals can be easily masked by the broad-band fluorescence
background, hampering interpretation of the spectra. Addi-
tionally, in most of these studies, a fiber-optic Raman probe
is required to access the tissues of interest in vivo. Although
a necessary and important step towards a widespread clinical
use, such fiber-based Raman technology using manageable
probes with real-time translation software is yet to be
developed [9].
In the light of image-guided surgery, a significant amount
of work has been done in the field of optical imaging. In
optical imaging, the properties of light emitted from a light
source (e.g., laser, LED, Xenon) are exploited to image
anatomic or chemical characteristics of tissue. Imaging of
optical contrast can be performed using either the properties
intrinsic to the tissue, or, analogous to many radiolabeled
agents, using ligands conjugated to an optically active
reporter to target a recognized disease biomarker [1]. In this
way, optical imaging could provide a valuable addition to
the current modalities of image-guided surgery. This review
outlines the various techniques, contrast agents, and camera
systems that are currently used for image-guided surgery.
Furthermore, an overview of the wide range of molecular
contrast agents that each target specific hallmarks of cancer
is provided and the perspectives on its future use in cancer
surgery are described.
Autofluorescence
Autofluorescence refers to the intrinsic fluorescence of the
tissue that is excited when activated by ultraviolet, visible,
or near-infrared (NIR) radiation of suitable wavelength.
Because cancerous transformation leads to morphologic and
biochemical alterations, which affect the optical properties of
the tissue, in some cases, the autofluorescence may actually
illuminate the structures of interest and can serve as a useful
diagnostic indicator [10]. This holds a significant advantage,
for there is no exogenous agent required which could
complicate regulatory approval for clinical use.
Using this technique, dysplastic and malignant tissues
have been shown to excite increased red fluorescence due to
an increase of endogenous porphyrins in their tissues and
decreased green fluorescence because of breakdown of
collagen cross links within the superficial stroma. Both
increase in the red/green fluorescence ratio and an increase
in NAD(P)H fluorescence are reported to be predictors of
dysplasia and malignancy [11–14].
Two-photon fluorescence microscopy is a relatively novel
technique to study cell biology in vitro and in vivo. This
technology, based on the quasi-simultaneous absorption of
two or more photons, requires less signal intensity, increases
penetration depth to several millimeters and offers better
axial resolution compared to one-photon fluorescence
techniques. It has been used for dynamic imaging of tumor
growth and invasion in vivo using a modified skin-fold
chamber for orthotopic implantation [15]. To our knowledge,
no intra-operative applications of this technique have been
described.
However, despite the initial optimism, the determination
of the various mechanisms that influence the signal has
proven to be a complex process [16]. These studies clearly
indicate a robust correlation between optical signature and
the phase of the disease progression but as long as the
relative contributions of the individual components are not
isolated, the specificity of the tumor detection remains
difficult to determine.
Optical Imaging with Conventional
Fluorescence
Optical imaging revolves around the concept of signal-to-
background ratio (SBR), which in cancer imaging is usually
referred to as the tumor-to-background ratio. To detect the
targeted (tumor) cells, the tumor-specific signal must be
significantly discriminated from the nonspecific surrounding
signals.
The conventional fluorescent techniques use probes in
the visible light spectrum (∼400-600 nm), which is not
optimal for intra-operative image-guided surgery. This
spectrum is associated with a relatively high level of
nonspecific background light, resulting in a low SBR. In
addition, the absorption of visible light by biological
chromophores, in particular hemoglobin, limits the pene-
tration depth to a few millimeters.
Optical Imaging with Near-infrared
Fluorescence
Over the last decade, the development of NIR fluorophores
and nanomaterials has led to a revolution in optical imaging.
The concept of using NIR light has proven a crucial step
towards its application in intra-operative image-guided
surgery.
The combination of light absorption by hemoglobin in the
visible light spectrum (G600 nm) and other components (e.g.,
water and lipids) in the infrared range (9900 nm), offers an
optical imaging window from approximately 650-900 nm in
which the absorption coefficient of tissue is at a minimum.
Consequently, light scattering and autofluorescence are
decreased and tissue penetration is increased in this spectrum,
stimulatingthe development ofa range ofprobesthatprovide a
high SBR.
Near-infrared Spectroscopy
The intrinsic optical absorption signals of blood, water, and
lipid, correlated with increased hemoglobin concentration due
to angiogenesis and decreased hemoglobin saturation due to
hypermetabolism,canbeutilizedinNIRspectroscopytodetect
andlocalizecancer[17].Usingthree-dimensionalparallel-plate
diffuse optical tomography [18] or time-domain optical
mammography(Softscan®,AdvancedResearchTechnologies,
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breast,variationsinthefunctionalandstructuralNIRproperties
(e.g., scattering, oxy-, and deoxy-hemoglobin concentrations)
were observed, enabling differentiation between benign and
[19] malignant tumors. However, these techniques are not
directly suitable for intra-operative use.
Non-targeted Exogenous Contrast Agents
Various nonspecific agents have been developed that are
currently available for research and clinical use (e.g.,
fluorescein, indocyanine green (ICG), cresyl violet acetate,
toluidine blue, Lugol’s iodine). ICG (emission peak,
830 nm) has optical properties that are suitable for NIR
imaging, which have been exploited for imaging of angio-
genesis and identification of hepatic segments for facilitation
of hepatic resection [20, 21]. Moreover, promising results
have been reported in the field of sentinel lymph node
mapping, which we will describe later. In principle, because
these agents are not tumor specific, they are not optimally
suited for determination of the tumor-free margin. Very
recently however, real-time demarcation of small and
grossly unidentifiable liver cancers using ICG has been
described due to the disordered biliary excretion of ICG in
cancer tissues and noncancerous liver tissues compressed by
the tumor [22].
Non-targeted Activatable Organic
Fluorophores
When focusing on the expansive character of the tumor
resulting from up-regulation of proteolytic enzymes, a
different strategy can be followed by using activatable
fluorophores. This method allows detection of proteases that
are relatively abundant in malignant tissue, which can be
associated with specific characteristics (e.g., invasive,
aggressive, or metastatic tendency) of the tumor. These
agents are injected in a quenched (i.e., inactivated) state,
resulting in minimal fluorescence at the time of adminis-
tration. When cleaved by specific enzymes, the agent
becomes dequenched (i.e., activated), and fluorescence can
be measured. Due to the cleavability, these probes have
higher SBR when compared to nonspecific probes.
Weissleder et al. have developed a series of such
cleavable NIR probes that are activated by proteases such
as cathepsins and matrix metalloproteinases [23, 24] that are
currently commercially available (Visen Medical, Boston,
MA, USA). A different quencher mechanism, using an
inhibitory domain made up of negatively charged residues
fused to activatable polyarginine-based cell-penetrating
peptides has been described by Tsien et al. [25] for use in
the detection of matrix metalloproteinases. However, these
agents are not targeting specific molecules in cancer cells
only. Cathepsins and matrix metalloproteinases are also
produced by macrophages and neutrophils, and hence are
abundant in inflammatory tissue [26] and in cerebral
ischemia [27]. Nonetheless, our preclinical results in rats
(Mieog et al., in press) and the previously mentioned studies
are very promising (Fig. 2).
Targeted Organic Fluorophores
Essentialforthelimitlessreplicativepotentialoftumorcellsare
the increased metabolism and expression of growth signaling
receptors, combined with increased tumor angiogenesis to
supply sufficient oxygen and nutrients. These features can be
exploited by targeted NIR fluorescent agents, which provide
molecularly specific detection of cancer cells (Fig. 1). In these
agents, the NIR fluorophore has been conjugated to a specific
targeting ligand or monoclonal antibody. Such agents have
shown excellent SBR in whole animals and images can be
collected over longer periods than the short-lived radiotracers
labeled with fluorine-18 or carbon-11. For increased growth
factorreceptorexpression,severalgroupshavereportedtheuse
of various monoclonal antibodies coupled to fluorophores for
imaging of the epidermal growth factor (EGF) receptor, Her2/
neu receptor, or vascular endothelial growth factor (VEGF)
receptor in all kinds of different tumors [28–30]. In these
Fig. 2. Detection of breast cancer using the non-targeted activatable organic NIRF probe ProSense 680™ in a syngeneic rat
model of primary breast cancer. a 3-Dimensional fusion of contrast-enhanced micro-CT and fluorescence imaging. In
collaboration with J. Dijkstra, Division of Image Processing, LUMC. b NIRF image-guided resection of one of the primary
tumors using the Fluobeam™.
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703 nm) and Alexa Fluor 750 (excitation 749 nm, emission
775 nm) were used.
An exciting new approach, similar to the non-targeted
activatable organic fluorophores described earlier, is the
use of quenched fluorophores conjugated to tumor-targeting
monoclonal antibodies. This approach was successfully
explored by Kobayashi and et al. [31]. Kobayashi et al. used
avidin (targeting the d-galactose receptor) and trastuzumab
(HER2 mAb) labeled with the TAMRA (fluorophore)-QSY7
(quencher) pair. After internalization into the cell, the probe
was cleaved, resulting in dequenching and target-specific
fluorescence imaging with high SBR.
A fluorophore bound toa specificligandcan be internalized
and its uptake can be monitored, as was illustrated with
VEGF and EGF [32, 33]. The latter was conjugated to the
IRdye800CW (Li-Cor Bioscience, Lincoln, NE, USA), a
fluorophore with a peak excitation at 785 nm and
emission at 810 nm. Due to the higher excitation
frequency, IRdye800CW has even better tissue penetra-
tion and SBR than Cy 5.5 [34].
In strategies for imaging (tumor) angiogenesis, a crucial
concept has been the targeting of alpha-v-beta-3 (αvβ3)
integrin, a critically important adhesion molecule in the
regulation of angiogenesis. This molecule can be found at
the sprouting ends of newly formed blood vessels but also
frequently on many epithelial tumor cells. High expression
of adhesion receptors can be detected when targeting αvβ3
integrin by cyclic arginine-glycine-aspartate (cRGD) con-
jugated to Cy 5.5 or IRdye800CW [35]. The use of the
quenching technique has been described in this respect as
well, by means of a quenched cRGD molecule (RAFT-
c(-RGDfK-)(4)-Cy5-SS-Q), which becomes activated
upon internalization into the cell [36].
Increased αvβ3 expression can also be visualized by direct
binding of a small peptidomimetic antagonist coupled to a
NIR fluorescent dye (VivoTag-S680), known as Integri-
Sense (Visen Medical, Boston, MA, USA). IntegriSense has
a much higher specificity for αvβ3 integrin compared to
RGD-based probes. It was shown to co-localize at the
surface of both αvβ3 integrin positive endothelial and tumor
cells. The signal is additionally enhanced by the internal-
ization into αvβ3 integrin positive tumor cells, leading to a
slower clearance of the probe from tumors compared to
surrounding tissues [37]. This probe has successfully been
used to visualize liver metastasis from colon cancer in a rat
model. It is important to note that most fluorescent dyes are
related to high background signal in the liver, kidneys, and
bladder due to biodistribution and clearance of the agent,
whereas in this study, the liver metastases could be clearly
demarcated (Mieog & Hutteman et al., submitted).
In analogy with PET technology, targeting the increase
in glucose metabolism due to increased expression of
membrane glucose transporter proteins (i.e., GLUT) is a
promising strategy. Very interesting results have recently
been published regarding imaging of glucose uptake, as
reflected by increased GLUT, in intracranial gliomas
using the glucose analog 2-deoxyglucose conjugated with
IRDye800CW [38].
Nanoparticles
Quantum dot nanoparticles are small crystals (2–10 nm
diameter), made of inorganic semiconductor materials. They
possess several physical properties that make them appealing
for use as imaging reporters. The high quantum yields result
in high signal intensity, enabling detection at lower concen-
trations compared to organic fluorophores. In addition, the
fluorescence emission spectra can be tuned, depending on
their size, allowing for multiplexed imaging. Furthermore,
quantum dot nanoparticles have proven to be photostable
and have the possibility to target multiple biomarkers, due to
their ability to contain multiple probe molecules. Finally,
multimodal targeted quantum dot-based nanoparticles coated
with paramagnetic micellar shells have been described,
allowing for both optical and magnetic resonance detection
of tumor angiogenesis (Fig. 3)[ 39].
However, the toxicity of quantum dot nanoparticles is a
serious concern. The problem is that most quantum dots
(albeit a very diverse group of substances) are based on
heavy metal cores (e.g., Cd-Se, Cd-Te), which have been
reported to be cytotoxic in their soluble form due to the
release of toxic Cd
2+ ions and their surface chemistry and
stability towards aggregation [40, 41]. These issues raise
such significant hazards that, at present, clinical application
of quantum dot nanoparticles does not seem feasible.
Silica nanoparticles have been developed as an alternative
to quantum dots that combine the versatility and functionality
of organic dyes with the stability and biocompatibility of the
silica surface [42]. In a recent study, the biodistribution,
including long-term quantitative tissue distribution, subcellular
distribution, and the toxicity of silica nanoparticles were
assessed in a mouse model. The results indicated that the small
sizeofthesilicananoparticlesresultedinhighpermeabilityand
lengthy accumulation of the agent in lungs, liver, and spleen
and could potentially cause liver injury when intravenously
injected [43]. Because size, surface area, surface chemistry,
solubility,andshapeareprobablyallkeyfeaturesthatplayarole
in determining the harmful potential for engineered nano-
materials [44], extensive research will have to be performed
over the coming years in order to address these issues.
In conclusion, several strategies are at hand in the
optical imaging field using NIR with probes that can
reach significant SBR and can be combined with targeting
ligands to increase the specificity and sensitivity of tumor
detection (Fig. 4). Because organic fluorophores are more
biocompatible than inorganic agents, it is expected that, when
using the former agents, toxicity issues will play a minor role,
as illustrated by ICG and fluorescein which are already widely
used in the clinic. However, for clinical translation of these
results, pharmacokinetic studies are required for each fluoro-
phore or fluorophore conjugate.
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The properties of NIR optical imaging are clearly perfectly
suited for real-time fluorescence imaging during surgery. If
adequate imaging resolution can be achieved, intra-operative
tumor visualization may improve radical resection without
unnecessary damage to healthy tissue and has the potential
to more accurately assess tumor margins during surgery.
Moreover, through biochemical changes involved in the
earliest stages of neoplastic development, this technique
promises to identify malignant lesions before they become
visible to the naked eye or currently available intra-operative
imaging modalities.
Considering its wide range of applications, one could
wonder why this technique has just only recently emerged.
Essentially, the development has been hampered by the lack of
suitable NIR probes and dedicated camera systems for the
intra-operative visualization of these probes. As described
above, NIR probe development has made significant progress,
resulting in the urgent need for intra-operative imaging
systems.
Conventionalcamerasystemsarelimitedtosingle-bandNIR
cameras, which have two drawbacks: they do not enable
separation of autofluorescence from the probe signal and it is
not possible to correct for geometric and intensity distortions
caused by photon-tissue interactions. Dedicated NIR camera
systems that have been used for intra-operative optical image-
guided surgery include the Photodynamic Eye (PDE; Hama-
matsu Photonics, Hamamatsu City, Japan) and a self-build
system, the Fluorescence-assisted Resection and Exploration
(FLARE™)[ 45], fromtheFragioni laboratory (Brookline, MA,
USA).Currently, twosmaller systemshavebeen developed:the
Mini-FLARE™ from the Frangioni laboratory [46]a n dt h e
Fluobeam from Fluoptics (Grenoble, France; Fig. 5).
Fig. 3. Magnetic resonance and optical molecular imaging of tumor angiogenesis using alpha-v-beta-3 targeted multimodal
quantum dot-based nanoparticles. T2-weighted images (a, e), collected before the nanoparticles were injected, show the
contour of the tumor on the flank. T1-weighted images (b, c, f, g) with TR=800 ms were measured before (b, f) and 45 min after
(c, g) the injection of the nanoparticles. The arrows in (c, g) indicate bright (positive contrast) regions in the periphery of the
tumor. In d, h, pixels in the tumor with signal enhancement of at least three times the noise level are color coded according to
the pseudo-color scale on the right. i, j Bioluminescence imaging and fluorescence imaging of a Balb/c nude mouse with a
luciferase-expressing renal carcinoma tumor after injection of luciferin (i). The strong bioluminescence signal is indicative of
tumor growth in the right kidney. This signal colocalizes with a strong fluorescence signal (j) originating from intravenously
administrated nanoparticles that are accumulated in the tumor. Republished with kind permission from Mulder WJ, Castermans
K, van Beijnum JR et al. Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum
dots. Angiogenesis. 2009;12(1):17-24.
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correction for photon-tissue interaction and spectral unmix-
ing of fluorescent signals. In preclinical studies, spectral
unmixing has already proven to be superior to conventional
fluorescence detection and was shown to greatly improve
sensitivity and localization accuracy of NIR cameras [47–
49]. However, these systems are not able to unmix the
signals in real-time, which would be required for intra-
operative image-guided surgery.
Currently, two new camera systems have been developed
that can detect and unmix NIR fluorescence in real-time.
The first system has been developed by the group of
Ntziachristos [50], which implements a correction scheme
that improves the accuracy of epi-illumination fluores-
cence images for light intensity variation in tissues. The
implementation is based on the use of three cameras
operating in parallel, utilizing a common main objective,
which allows for the concurrent collection of color,
fluorescence, and light attenuation images at the excitation
wavelength from the same field of view. The correction is
b a s e do nar a t i oa p p r o a c ho ff l u o r e s c e n c eo v e rl i g h t
attenuation images. Color images and video are used for
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Fig. 4. Illustration of the use of two fluorescent agents with emission on different wavelengths, showing the simultaneous
detection of an MDA-MB231 breast cancer bone metastases in the right hind limb of a nude mouse. MDA-MB231 cells express
relatively high levels of EGFR and are highly osteolytic. Nonspecific uptake of the probes in the bladder is also shown. a
Fluorescent image showing the blue signal of MMPSense™ 680; green is tissue autofluorescence. b Fluorescent image
showing the red signal of IRDye® 800CW EGF; green is tissue autofluorescence. c Fluorescent composite image showing both
signals simultaneously (purple); green is tissue autofluorescence. d Graphic showing peak signal intensity of MMPSense™ 680
at 700 nm (blue line), unmixed from autofluorescence (green line). e Graphic showing peak signal intensity of IRDye® 800 CW
EGF at 800 nm (red line), unmixed from autofluorescence (green line). The MMPSense signal covers a larger area compared to
the IRDye® 800CW EGF signal. This is most probably due to the fact that IRDye® 800CW EGF only detects the MDA-MB231
cells, whereas MMPSense also detects the highly increased osteoclastic bone resorption (ostelytic lesion) as a result of matrix
metalloproteinase-9 expression of resorbing osteoclasts. AF autofluorescence.
Fig. 5. Near-infrared intra-operative camera systems. a FLARE™ camera system (www.frangionilab.org). b Artist impression
of Fluobeam™ (www.fluoptics.com). c Artemis™ camera system (www.O2view.com). d The Photodynamic Eye (Hamamatsu
Photonics, Hamamatsu City, Japan).
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fluorescence images. The second camera system is the
Artemis, developed by O2view (Marken, The Nether-
lands). The Artemis is a real-time stereoscopic imaging
system that combines visible light with NIR light images.
It is equipped with a laser diode and the camera system
allows additional 3D visualization of fluorescent mole-
cules, superimposed on color stereoscopic vision. It has
the potential to make multispectral images because it uses
a five-channel prism (covering the range from 400–
1000 nm) enabling the capture of images from five
different CCD/CMOS sensors simultaneously with five
different color bands. The Artemis also has a zoom
function and provides real 3D pictures by grabbing two
different images coming from two different optical axes.
This new system will be tested in our institute (Leiden
University Medical Center) to optimize the Artemis for
intra-operative image-guided surgery (CTMM MUSIS
project: www.ctmm.com)
Sentinel Lymph Node Mapping
The first steps for translation of this technique to the clinic
have been made in sentinel lymph node mapping. The
sentinel lymph node is the first lymph node to which the
lymphatic fluid coming from the tumor drains and in which
tumor cells will first metastasize. Currently, lymphatic
imaging is performed using dye-injection, nuclear imaging,
CT, and MRI [51], which each has their specific limitations
regarding sensitivity, resolution, exposure to radioactivity, or
practical use. NIR fluorescence imaging allows for high spatial
and temporal resolution without ionizing radiation, making it
an easy-to-use and safe technique. With parallel imaging of
visible and near-infrared light,the contrast agentscan be traced
to the sentinel lymph nodes in real-time, without affecting the
visual appearance of the surgical field.
Considering the recent clinical results using intra-
operative NIR fluorescence cameras [45, 52] or portable
NIR-imaging devices [53], sentinel lymph node mapping is
one of the most promising clinical applications for NIR
fluorescence imaging in the field of oncology.
Other Surgical Applications
Intra-operative optical imaging camera systems are being
developed resulting in the detection of a variety of tumors in
mice during surgical procedures. In addition to intra-
operative tumor detection, endoscopic systems are under
development for diagnostic and surgical applications [54].
In neurosurgery, the use of 5-aminolevulinic acid for
detection of malignant gliomas by optical imaging techni-
ques has been recently studied. The intra-operative use for
fluorescence guidance has been described in a phase II trial
as an effective adjunct in the surgery of recurrent malignant
gliomas [55].
Future Directions
The use of NIR fluorescence optical imaging in the field of
sentinel lymph node mapping is rapidly expanding in
clinical oncology. ICG, approved by the Food and Drug
Administration (FDA) for various other applications, will
play a major role in this respect, potentially demonstrating
the clinical advantage over current lymph node mapping
protocols. However, FDA approval of organic fluorophores
is a necessary step towards clinical targeting of tumor
specific signals. Once these agents are also found to be safe,
it is anticipated that the initial steps will be taken in
conjugating them to already FDA approved and clinically
used monoclonal antibodies (e.g., cetuximab, bevacizumab).
In the following years, FDA approval of the activatable agents
is required to fully exploit the possibilities of optical imaging,
and thereby enhance the specificity and sensitivity of this
technique. Furthermore, if the toxicity issues of nanoparticles
can be solved, interesting developments in that field can be
expected due to the aforementioned advantages regarding
multimodality and multitargeted imaging. All these develop-
ments will have to be accompanied by parallel development of
adequate, manageable, intra-operative camera systems.
Very recently, intriguing research regarding undetectable
fluorescence of non-fluorescent, light-absorbing molecules
has been described by stimulating photon emission techniques
[56]. However, as yet far from practical applications, these
studies hold promising possibilities for clinical or maybe even
intra-operative use in the years to come.
The ultimate goal of the research that is presented in this
article is intra-operative tumor imaging with optimal
sensitivity and specificity. In order to achieve this, it is
anticipated that a combination of different strategies that
each target specific hallmarks of cancer will prove to be a
key factor in guiding the oncologic surgeon towards optimal
radical resection and clinical results.
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